Based on the DSMB decision, Eli Lilly and Company provide provide $ 000 milestone payment to BioMS as part of the conditions of the license and Collaboration Agreement infecciones-ent.html . – We are Safety Board Safety Board ‘s recommendation, said Kevin Giese, President and CEO of BioMS Medical. This positive assessment is an important milestone for BioMS and our partner, Eli Lilly and Company, and brings us a step closer to our goal of this important therapy for patients with multiple sclerosis. – We are analyzing the results of the interim report happy and looking forward to the final efficacy and safety data from this trial in the next year, said Dr. Mark Freedman, Professor of Neurology at the University of Ottawa and Director of the MS Research Clinic at Ottawa Hospital. If successful, this novel therapy administered only twice per year, could help. A large underserved population with late stage MS .
About Multiple SclerosisMultiple sclerosis is thought to be the world as many as 2.5 million people, including about 75,000 in Canada, 000 influence in the United States and more than 500,000 in Europe. It is a disease that affects more women than men, with onset typically occurring from 20 to 50 years. MS by damaged myelin, the protective sheath surrounding nerve fibers in the central nervous system, relapsing remitting from the brain to interferes interferes. Symptoms of MS may include vision problems, loss of balance, numbness, difficulty walking and paralysis. About 40 % of MS patients have the secondary progressive form of the disease. Continue reading